Neonatal gene therapy with a gamma retroviral vector in mucopolysaccharidosis VI cats

Molecular Therapy

Volumn 20, Issue 5, 2012, Pages 898-907

  Ponder, Katherine P ^a   O'Malley, Thomas M ^b   Wang, Ping ^b   O'Donnell, Patricia A ^b   Traas, Anne M ^b   Knox, Van W ^b   Aguirre, Gustavo A ^b   Ellinwood, N Matthew ^b   Metcalf, Jason A ^a   Wang, Bin ^a   Parkinson Lawrence, Emma J ^c   Sleeper, Meg M ^b   Brooks, Doug A ^c   Hopwood, John J ^c   Haskins, Mark E ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c WOMEN S AND CHILDREN S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GLUCURONIDASE; N ACETYLGALACTOSAMINE 4 SULFATASE; RETROVIRUS VECTOR; SULFATASE; SULFATASE MODIFYING FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BONE DISEASE; BONE STRUCTURE; CAT; CLINICAL FEATURE; CONTROLLED STUDY; DRUG RESPONSE; ENZYME ACTIVITY; FACE DYSMORPHIA; FEMALE; GAIT DISORDER; LIVER LEVEL; MALE; MAROTEAUX LAMY SYNDROME; NEWBORN; NONHUMAN; NUCLEIC ACID ANALYSIS; URINALYSIS; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

CANIS FAMILIARIS; FELIDAE; MUS;

EID: 84862804825     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.9     Document Type: Article

References (50)

1. Neufeld, EF and Muenzer, J. (2001). The Mucopolysaccharidoses. In: C.R. Scriver, A.L. Beaudet, W.S. Sly and D. Valle (eds). Metabolic and Molecular Basis of Inherited Disease. New York, McGraw Hill, pp. 3421-3452.
2. Meikle, PJ, Hopwood, JJ, Clague, AE and Carey, WF (1999). Prevalence of lysosomal storage disorders. JAMA 281: 249-254. (Pubitemid 29058114)
3. Azevedo, AC, Schwartz, IV, Kalakun, L, Brustolin, S, Burin, MG, Beheregaray, AP et al. (2004). Clinical and biochemical study of 28 patients with mucopolysaccharidosis type VI. Clin Genet 66: 208-213. (Pubitemid 39232782)
4. Tan, CT, Schaff, HV, Miller, FA Jr, Edwards, WD and Karnes, PS (1992). Valvular heart disease in four patients with Maroteaux-Lamy syndrome. Circulation 85: 188-195.
5. Fesslová, V, Corti, P, Sersale, G, Rovelli, A, Russo, P, Mannarino, S et al. (2009). The natural course and the impact of therapies of cardiac involvement in the mucopolysaccharidoses. Cardiol Young 19: 170-178.
6. Braunlin, EA, Harmatz, PR, Scarpa, M, Furlanetto, B, Kampmann, C, Loehr, JP et al. (2011). Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management. J Inherit Metab Dis 34: 1183-1197.
7. Horovitz, DD, Magalhães, Tde S, E Costa, AP, Carelli, LE, E Silva, DS, de Linhares E Riello, AP et al. (2011). Spinal cord compression in young children with type VI mucopolysaccharidosis. Mol Genet Metab 104: 295-300.
8. Dangel, JH (1998). Cardiovascular changes in children with mucopolysaccharide storage diseases and related disorders-clinical and echocardiographic findings in 64 patients. Eur J Pediatr 157: 534-538. (Pubitemid 28311476)
9. Golda, A, Jurecka, A and Tylki-Szymanska, A (2011). Cardiovascular manifestations of mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome). Int J Cardiol Int J Cardiol, published online (doi:10.1016/j.ijcard.2011.06.097).
10. Yogalingam, G, Litjens, T, Bielicki, J, Crawley, AC, Muller, V, Anson, DS et al. (1996). Feline mucopolysaccharidosis type VI. Characterization of recombinant N-acetylgalactosamine 4-sulfatase and identification of a mutation causing the disease. J Biol Chem 271: 27259-27265. (Pubitemid 26367277)
11. Haskins, ME, Jezyk, PF, Desnick, RJ and Patterson, DF (1981). Animal model of human disease: Mucopolysaccharidosis VI Maroteaux-Lamy syndrome, Arylsulfatase B-deficient mucopolysaccharidosis in the Siamese cat. Am J Pathol 105: 191-193. (Pubitemid 12241801)
12. Haskins, ME, Bingel, SA, Northington, JW, Newton, CD, Sande, RD, Jezyk, PF et al. (1983). Spinal cord compression and hindlimb paresis in cats with mucopolysaccharidosis VI. J Am Vet Med Assoc 182: 983-985. (Pubitemid 13101134)
13. Sleeper, MM, Kusiak, CM, Shofer, FS, O'Donnell, P, Bryan, C, Ponder, KP et al. (2008). Clinical characterization of cardiovascular abnormalities associated with feline mucopolysaccharidosis I and VI. J Inherit Metab Dis 31: 424-431.
14. Haskins, ME, Aguirre, GD, Jezyk, PF and Patterson, DF (1980). The pathology of the feline model of mucopolysaccharidosis VI. Am J Pathol 101: 657-674. (Pubitemid 11203654)
15. Walkley, SU, Thrall, MA, Haskins, ME, Mitchell, TW, Wenger, DA, Brown, DE et al. (2005). Abnormal neuronal metabolism and storage in mucopolysaccharidosis type VI (Maroteaux-Lamy) disease. Neuropathol Appl Neurobiol 31: 536-544. (Pubitemid 41337787)
16. Simonaro, CM, D'Angelo, M, Haskins, ME and Schuchman, EH (2005). Joint and bone disease in mucopolysaccharidoses VI and VII: identification of new therapeutic targets and biomarkers using animal models. Pediatr Res 57(5 Pt 1): 701-707. (Pubitemid 40578042)
17. Simonaro, CM, Ge, Y, Eliyahu, E, He, X, Jepsen, KJ and Schuchman, EH (2010). Involvement of the Toll-like receptor 4 pathway and use of TNF-alpha antagonists for treatment of the mucopolysaccharidoses. Proc Natl Acad Sci USA 107: 222-227.
18. Ausseil, J, Desmaris, N, Bigou, S, Attali, R, Corbineau, S, Vitry, S et al. (2008). Early neurodegeneration progresses independently of microglial activation by heparan sulfate in the brain of mucopolysaccharidosis IIIB mice. PLoS ONE 3: e2296.
19. Baldo, G, Wu, S, Howe, RA, Ramamoothy, M, Knutsen, RH, Fang, J et al. (2011). Pathogenesis of aortic dilatation in mucopolysaccharidosis VII mice may involve complement activation. Mol Genet Metab 104: 608-619.
20. Lee, V, Li, CK, Shing, MM, Chik, KW, Lam, CW, Tsang, KS et al. (2000). Umbilical cord blood transplantation for Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI). Bone Marrow Transplant 26: 455-458. (Pubitemid 30649564)
21. Turbeville, S, Nicely, H, Rizzo, JD, Pedersen, TL, Orchard, PJ, Horwitz, ME et al. (2011). Clinical outcomes following hematopoietic stem cell transplantation for the treatment of mucopolysaccharidosis VI. Mol Genet Metab 102: 111-115.
22. Herskhovitz, E, Young, E, Rainer, J, Hall, CM, Lidchi, V, Chong, K et al. (1999). Bone marrow transplantation for Maroteaux-Lamy syndrome (MPS VI): long-term follow-up. J Inherit Metab Dis 22: 50-62. (Pubitemid 29078131)
23. Kornfeld, S (1992). Structure and function of the mannose 6-phosphate/insulinlike growth factor II receptors. Annu Rev Biochem 61: 307-330.
24. Simonaro, CM, Haskins, ME, Kunieda, T, Evans, SM, Visser, JW and Schuchman, EH (1997). Bone marrow transplantation in newborn rats with mucopolysaccharidosis type VI: biochemical, pathological, and clinical findings. Transplantation 63: 1386-1393. (Pubitemid 27237439)
25. Harmatz, P, Giugliani, R, Schwartz, IV, Guffon, N, Teles, EL, Miranda, MC et al.; MPS VI Study Group. (2008). Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase. Mol Genet Metab 94: 469-475.
26. Scarpa, M, Barone, R, Fiumara, A, Astarita, L, Parenti, G, Rampazzo, A et al. (2009). Mucopolysaccharidosis VI: the Italian experience. Eur J Pediatr 168: 1203-1206.
27. Decker, C, Yu, ZF, Giugliani, R, Schwartz, IV, Guffon, N, Teles, EL et al. (2010). Enzyme replacement therapy for mucopolysaccharidosis VI: Growth and pubertal development in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase. J Pediatr Rehabil Med 3: 89-100.
28. Lin, HY, Chen, MR, Chuang, CK, Chen, CP, Lin, DS, Chien, YH et al. (2010). Erratum to: Enzyme replacement therapy for mucopolysaccharidosis VI-experience in Taiwan. J Inherit Metab Dis, published online (doi:10.1007/s10545-010-9212-5).
29. Giugliani, R, Carvalho, CG, Herber, S and de Camargo Pinto, LL (2011). Recent Advances in Treatment Approaches of Mucopolysaccharidosis VI. Curr Pharm Biotechnol 12: 956-962.
30. McGill, JJ, Inwood, AC, Coman, DJ, Lipke, ML, de Lore, D, Swiedler, SJ et al. (2010). Enzyme replacement therapy for mucopolysaccharidosis VI from 8 weeks of age-a sibling control study. Clin Genet 77: 492-498.
31. Auclair, D, Hopwood, JJ, Brooks, DA, Lemontt, JF and Crawley, AC (2003). Replacement therapy in Mucopolysaccharidosis type VI: advantages of early onset of therapy. Mol Genet Metab 78: 163-174. (Pubitemid 36332018)
32. Crawley, AC, Brooks, DA, Muller, VJ, Petersen, BA, Isaac, EL, Bielicki, J et al. (1996). Enzyme replacement therapy in a feline model of Maroteaux-Lamy syndrome. J Clin Invest 97: 1864-1873. (Pubitemid 26129873)
33. Ponder, KP and Haskins, ME (2007). Gene therapy for mucopolysaccharidosis. Expert Opin Biol Ther 7: 1333-1345. (Pubitemid 47475654)
34. Brooks, DA, McCourt, PA, Gibson, GJ, Ashton, LJ, Shutter, M and Hopwood, JJ (1991). Analysis of N-acetylgalactosamine-4-sulfatase protein and kinetics in mucopolysaccharidosis type VI patients. Am J Hum Genet 48: 710-719. (Pubitemid 21891615)
35. Tessitore, A, Faella, A, O'Malley, T, Cotugno, G, Doria, M, Kunieda, T et al. (2008). Biochemical, pathological, and skeletal improvement of mucopolysaccharidosis VI after gene transfer to liver but not to muscle. Mol Ther 16: 30-37.
36. Cotugno, G, Annunziata, P, Tessitore, A, O'Malley, T, Capalbo, A, Faella, A et al. (2011). Long-term amelioration of feline Mucopolysaccharidosis VI after AAVmediated liver gene transfer. Mol Ther 19: 461-469.
37. Ponder, KP, Melniczek, JR, Xu, L, Weil, MA, O'Malley, TM, O'Donnell, PA et al. (2002). Therapeutic neonatal hepatic gene therapy in mucopolysaccharidosis VII dogs. Proc Natl Acad Sci USA 99: 13102-13107.
38. Xu, L, Haskins, ME, Melniczek, JR, Gao, C, Weil, MA, O'Malley, TM et al. (2002). Transduction of hepatocytes after neonatal delivery of a Moloney murine leukemia virus based retroviral vector results in long-term expression of beta-glucuronidase in mucopolysaccharidosis VII dogs. Mol Ther 5: 141-153. (Pubitemid 34144830)
39. Wang, B, O'Malley, TM, Xu, L, Vite, C, Wang, P, O'Donnell, PA et al. (2006). Expression in blood cells may contribute to biochemical and pathological improvements after neonatal intravenous gene therapy for mucopolysaccharidosis VII in dogs. Mol Genet Metab 87: 8-21. (Pubitemid 43003762)
40. Cosma, MP, Pepe, S, Annunziata, I, Newbold, RF, Grompe, M, Parenti, G et al. (2003). The multiple sulfatase deficiency gene encodes an essential and limiting factor for the activity of sulfatases. Cell 113: 445-456. (Pubitemid 36588748)
41. Dierks, T, Schmidt, B, Borissenko, LV, Peng, J, Preusser, A, Mariappan, M et al. (2003). Multiple sulfatase deficiency is caused by mutations in the gene encoding the human C(alpha)-formylglycine generating enzyme. Cell 113: 435-444. (Pubitemid 36588747)
42. Anson, DS, Muller, V, Bielicki, J, Harper, GS and Hopwood, JJ (1993). Overexpression of N-acetylgalactosamine-4-sulphatase induces a multiple sulphatase deficiency in mucopolysaccharidosis-type-VI fibroblasts. Biochem J 294 (Pt 3): 657-662. (Pubitemid 23286549)
43. Fraldi, A, Biffi, A, Lombardi, A, Visigalli, I, Pepe, S, Settembre, C et al. (2007). SUMF1 enhances sulfatase activities in vivo in five sulfatase deficiencies. Biochem J 403: 305-312. (Pubitemid 46596587)
44. Bielicki, J, Crawley, AC, Davey, RC, Varnai, JC and Hopwood, JJ (1999). Advantages of using same species enzyme for replacement therapy in a feline model of mucopolysaccharidosis type VI. J Biol Chem 274: 36335-36343.
45. Ponder, KP, Wang, B, Wang, P, Ma, X, Herati, R, Wang, B et al. (2006). Mucopolysaccharidosis I cats mount a cytotoxic T lymphocyte response after neonatal gene therapy that can be blocked with CTLA4-Ig. Mol Ther 14: 5-13. (Pubitemid 43899487)
46. Herati, RS, Knox, VW, O'Donnell, P, D'Angelo, M, Haskins, ME and Ponder, KP (2008). Radiographic evaluation of bones and joints in mucopolysaccharidosis I and VII dogs after neonatal gene therapy. Mol Genet Metab 95: 142-151.
47. Trobridge, GD (2011). Genotoxicity of retroviral hematopoietic stem cell gene therapy. Expert Opin Biol Ther 11: 581-593.
48. Metcalf, JA, Ma, X, Linders, B, Wu, S, Schambach, A, Ohlemiller, KK et al. (2010). A self-inactivating gamma-retroviral vector reduces manifestations of mucopolysaccharidosis I in mice. Mol Ther 18: 334-342.
49. Duffey, TA, Sadilek, M, Scott, CR, Turecek, F and Gelb, MH (2010). Tandem mass spectrometry for the direct assay of lysosomal enzymes in dried blood spots: application to screening newborns for mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). Anal Chem 82: 9587-9591.
50. Jackson, CE, Yuhki, N, Desnick, RJ, Haskins, ME, O'Brien, SJ and Schuchman, EH (1992). Feline arylsulfatase B (ARSB): isolation and expression of the cDNA, comparison with human ARSB, and gene localization to feline chromosome A1. Genomics 14: 403-411.